SH2 Domain-Containing Phosphatase 2 Is a Critical Regulator of Connective Tissue Mast Cell Survival and Homeostasis in Mice

Molecular and Cellular Biology

Volumn 32, Issue 14, 2012, Pages 2653-2663

  Sharma, Namit ^a   Kumar, Vijay ^a   Everingham, Stephanie ^a   Mali, Raghuveer Singh ^b   Kapur, Reuben ^b   Zeng, Li Fan ^c   Zhang, Zhong Yin ^c   Feng, Gen Sheng ^d   Hartmann, Karin ^e   Roers, Axel ^f   Craig, Andrew W B ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF COLOGNE   (Germany)

^f DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN SH2; PROTEIN TYROSINE PHOSPHATASE SHP; RAS PROTEIN; SH2 DOMAIN CONTAINING PHOSPHATASE 2; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL ASSAY; CELL LOSS; CELL MATURATION; CELL SURVIVAL; CONNECTIVE TISSUE; CONNECTIVE TISSUE MAST CELL; CONTROLLED STUDY; DOWN REGULATION; GENE DELETION; HOMEOSTASIS; KNOCKOUT GENE; MAST CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKIN ANAPHYLAXIS; SKIN CELL;

ANIMALS; APOPTOSIS REGULATORY PROTEINS; BASE SEQUENCE; CELL SURVIVAL; DNA PRIMERS; GENE SILENCING; HOMEOSTASIS; MAP KINASE SIGNALING SYSTEM; MAST CELLS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PASSIVE CUTANEOUS ANAPHYLAXIS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-KIT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SKIN;

MUS;

EID: 84864025903     PISSN: 02707306     EISSN: 10985549     Source Type: Journal    
DOI: 10.1128/MCB.00308-12     Document Type: Article

References (50)

1. Agosti V, et al. 2004. Critical role for Kit-mediated Src kinase but not PI 3-kinase signaling in pro T and pro B cell development. J. Exp. Med. 199:867- 878.
2. Aichberger KJ, et al. 2009. Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs. Blood 114:5342-5351.
3. Al-Nasiry S, Geusens N, Hanssens M, Luyten C, Pijnenborg R. 2007. The use of Alamar Blue assay for quantitative analysis of viability, migration and invasion of choriocarcinoma cells. Hum. Reprod. 22:1304 -1309.
4. Alfredsson J, Puthalakath H, Martin H, Strasser A, Nilsson G. 2005. Proapoptotic Bcl-2 family member Bim is involved in the control of mast cell survival and is induced together with Bcl-XL upon IgE-receptor activation. Cell Death Differ. 12:136 -144.
5. Arinobu Y, et al. 2005. Developmental checkpoints of the basophil/mast cell lineages in adult murine hematopoiesis. Proc. Natl. Acad. Sci. U. S. A. 102:18105-18110.
6. Arrandale JM, et al. 1996. Insulin signaling in mice expressing reduced levels of Syp. J. Biol. Chem. 271:21353-21358.
7. Besmer P, et al. 1993. The kit-ligand (steel factor) and its receptor ckit/W: pleiotropic roles in gametogenesis and melanogenesis. Dev. Suppl. 1993:125-137.
8. Bryce PJ, et al. 2004. Immune sensitization in the skin is enhanced by antigen-independent effects of IgE. Immunity 20:381-392.
9. Caughey GH. 2007. Mast cell tryptases and chymases in inflammation and host defense. Immunol. Rev. 217:141-154.
10. Chan G, et al. 2011. Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood 117:4253- 4261.
11. Chan RJ, Feng GS. 2007. PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase. Blood 109:862- 867.
12. Dance M, Montagner A, Salles JP, Yart A, Raynal P. 2008. The molecular functions of Shp2 in the Ras/mitogen-activated protein kinase (ERK1/2) pathway. Cell Signal. 20:453- 459.
13. Dudeck A, et al. 2011. Mast cells are key promoters of contact allergy that mediate the adjuvant effects of haptens. Immunity 34:973-984.
14. Franco CB, Chen CC, Drukker M, Weissman IL, Galli SJ. 2010. Distinguishing mast cell and granulocyte differentiation at the single-cell level. Cell Stem Cell 6:361-368.
15. Fukao T, et al. 2002. Selective loss of gastrointestinal mast cells and impaired immunity in PI3K-deficient mice. Nat. Immunol. 3:295-304.
16. Futami M, et al. 2011. G-CSF receptor activation of the Src kinase Lyn is mediated by Gab2 recruitment of the Shp2 phosphatase. Blood 118:1077- 1086.
17. Galli SJ, Grimbaldeston M, Tsai M. 2008. Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat. Rev. Immunol. 8:478-486.
18. Gerbaulet A, et al. 2011. Mast cell hyperplasia, B-cell malignancy, and intestinal inflammation in mice with conditional expression of a constitutively active kit. Blood 117:2012-2021.
19. Gilfillan AM, Rivera J. 2009. The tyrosine kinase network regulating mast cell activation. Immunol. Rev. 228:149 -169.
20. Grimbaldeston MA, et al. 2005. Mast cell-deficient W-sash c-kit mutant Kit W-sh/W-sh mice as a model for investigating mast cell biology in vivo. Am. J. Pathol. 167:835- 848.
21. Gurish MF, Boyce JA. 2006. Mast cells: ontogeny, homing, and recruitment of a unique innate effector cell. J. Allergy Clin. Immunol. 117:1285- 1291.
22. Hakim-Rad K, Metz M, Maurer M. 2009. Mast cells: makers and breakers of allergic inflammation. Curr. Opin. Allergy Clin. Immunol. 9:427- 430.
23. Ke Y, et al. 2007. Deletion of Shp2 in the brain leads to defective proliferation and differentiation in neural stem cells and early postnatal lethality. Mol. Cell. Biol. 27:6706-6717.
24. Kimura Y, et al. 2004. Targeted mutations of the juxtamembrane tyrosines in the Kit receptor tyrosine kinase selectively affect multiple cell lineages. Proc. Natl. Acad. Sci. U. S. A. 101:6015- 6020.
25. Kissel H, et al. 2000. Point mutation in kit receptor tyrosine kinase reveals essential roles for kit signaling in spermatogenesis and oogenesis without affecting other kit responses. EMBO J. 19:1312-1326.
26. Krajewska M, et al. 2008. Development of diabesity in mice with neuronal deletion of Shp2 tyrosine phosphatase. Am. J. Pathol. 172:1312-1324.
27. Lee I, et al. 2010. A suggested role for mitochondria in Noonan syndrome. Biochim. Biophys. Acta 1802:275-283.
28. Liu X, Qu CK. 2011. Protein tyrosine phosphatase SHP-2 (PTPN11) in hematopoiesis and leukemogenesis. J. Signal Transduct. 2011:195239.
29. Luciano F, et al. 2003. Phosphorylation of Bim-EL by Erk1/2 on serine 69 promotes its degradation via the proteasome pathway and regulates its proapoptotic function. Oncogene 22:6785- 6793.
30. Malbec O, et al. 2007. Peritoneal cell-derived mast cells: an in vitro model of mature serosal-type mouse mast cells. J. Immunol. 178:6465- 6475.
31. McPherson VA, et al. 2009. SH2 domain-containing phosphatase-2 protein-tyrosine phosphatase promotes Fc epsilon RI-induced activation of Fyn and Erk pathways leading to TNF alpha release from bone marrowderived mast cells. J. Immunol. 183:4940-4947.
32. Metcalfe DD. 2008. Mast cells and mastocytosis. Blood 112:946 -956.
33. Miyazaki T, Neff L, Tanaka S, Horne WC, Baron R. 2003. Regulation of cytochrome c oxidase activity by c-Src in osteoclasts. J. Cell Biol. 160:709- 718.
34. Mohi MG, et al. 2005. Prognostic, therapeutic, and mechanistic implications of a mouse model of leukemia evoked by Shp2 (PTPN11) mutations. Cancer Cell 7:179 -191.
35. Moller C, et al. 2005. Stem cell factor promotes mast cell survival via inactivation of FOXO3a-mediated transcriptional induction and MEKregulated phosphorylation of the proapoptotic protein Bim. Blood 106: 1330-1336.
36. Nagai H, et al. 2000. Different role of IL-4 in the onset of hapten-induced contact hypersensitivity in BALB/c and C57BL/6 mice. Br. J. Pharmacol. 129:299 -306.
37. Neel BG, Gu H, Pao L. 2003. The 'Shp'ing news: SH2 domain-containing tyrosine phosphatases in cell signaling. Trends Biochem. Sci. 28:284 -293.
38. Roskoski R, Jr. 2005. Signaling by Kit protein-tyrosine kinase-the stem cell factor receptor. Biochem. Biophys. Res. Commun. 337:1-13.
39. Salvi M, et al. 2002. Characterization and location of Src-dependent tyrosine phosphorylation in rat brain mitochondria. Biochim. Biophys. Acta 1589:181-195.
40. Salvi M, et al. 2004. Tyrosine phosphatase activity in mitochondria: presence of Shp-2 phosphatase in mitochondria. Cell. Mol. Life Sci. 61: 2393-2404.
41. Samayawardhena LA, Kapur R, Craig AW. 2007. Involvement of Fyn kinase in Kit and integrin-mediated Rac activation, cytoskeletal reorganization, and chemotaxis of mast cells. Blood 109:3679 -3686.
42. Saxton TM, et al. 1997. Abnormal mesoderm patterning in mouse embryos mutant for the SH2 tyrosine phosphatase Shp-2. EMBO J. 16:2352- 2364.
43. Scholten J, et al. 2008. Mast cell-specific Cre/loxP-mediated recombination in vivo. Transgenic Res. 17:307-315.
44. Serve H, Hsu YC, Besmer P. 1994. Tyrosine residue 719 of the c-kit receptor is essential for binding of the P85 subunit of phosphatidylinositol (PI) 3-kinase and for c-kit-associated PI 3-kinase activity in COS-1 cells. J. Biol. Chem. 269:6026-6030.
45. Timokhina I, Kissel H, Stella G, Besmer P. 1998. Kit signaling through PI 3-kinase and Src kinase pathways: an essential role for Rac1 and JNK activation in mast cell proliferation. EMBO J. 17:6250-6262.
46. Xu D, et al. 2010. A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cells. Blood 116:3611-3621.
47. Yang W, et al. 2006. An Shp2/SFK/Ras/Erk signaling pathway controls trophoblast stem cell survival. Dev. Cell 10:317-327.
48. Yu M, et al. 2006. The scaffolding adapter Gab2, via Shp-2, regulates kit-evoked mast cell proliferation by activating the Rac/JNK pathway. J. Biol. Chem. 281:28615-28626.
49. Zhang EE, Chapeau E, Hagihara K, Feng GS. 2004. Neuronal Shp2 tyrosine phosphatase controls energy balance and metabolism. Proc. Natl. Acad. Sci. U. S. A. 101:16064 -16069.
50. Zhang X, et al. 2010. Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2). J. Med. Chem. 53:2482-2493.